A RANDOMIZED PILOT STUDY OF SYSTEMIC IMMUNOSUPPRESSION IN THE TREATMENT OF AGE-RELATED MACULAR DEGENERATION WITH CHOROIDAL NEOVASCULARIZATION

• DOI: 10.1097/iae.0b013e3181e7978e
• Publication Date: 2010-09-16T11:23:19Z
• Authors: Robert B Nussenblatt; Gordon Byrnes; H Nida Sen; Steven Yeh; Lisa Faia; Catherine Meyerle; Keith Wroblewski; Zhuqing Li; Baoying Liu; Emily Chew; Patti R Sherry; Penelope Friedman; Fred Gill; Frederick Ferris
• Keywords: Daclizumab; Immunosuppression; Metamorphopsia; Aflibercept

Age-related macular degeneration remains the leading cause of irreversible blindness in United States and developed world. Intravitreal injections anti–vascular endothelial growth factor (VEGF) medications have become standard care for treatment wet form disease. Recent reports demonstrated an association with various immune factors. We aimed to investigate effect immunosuppressive therapy clinical course compared anti-VEGF plus one three systemic therapies versus alone recurrent choroidal neovascularization associated age-related degeneration.